2020
Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions
Chen PH, Bossuyt V, Reisenbichler E. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions. Human Pathology 2020, 108: 68-75. PMID: 33245988, DOI: 10.1016/j.humpath.2020.11.009.Peer-Reviewed Original ResearchConceptsMalignant phyllodes tumorPhyllodes tumorBenign tumorsLymphoid enhancer-binding factor 1Fibroepithelial lesionsTissue microarrayEnhancer-binding factor 1LEF-1 expressionMalignant tumorsBorderline/malignant phyllodes tumorsΒ-cateninStromal componentsNuclear expressionWorld Health Organization criteriaMetastatic phyllodes tumorWnt/β-catenin pathway activationAlternative treatment optionBorderline phyllodes tumorWnt/β-catenin pathwayFactor 1Β-catenin pathway activationE-cadherin immunohistochemistryWnt/β-catenin signalingΒ-catenin pathwayNuclear β-catenin stainingBilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing
Chen PH, Hui P, Buza N. Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing. International Journal Of Gynecological Pathology 2020, 39: 193-198. PMID: 30676431, DOI: 10.1097/pgp.0000000000000579.Peer-Reviewed Case Reports and Technical NotesConceptsSignet-ring stromal tumorStromal tumorsNext-generation sequencing analysisBilateral solid ovarian tumorsBilateral ovarian massesFOXL2 mutation testingSolid ovarian tumorSignet ring cell morphologySmooth muscle actinUnderlying genetic abnormalitiesPCR-Sanger sequencingNuclear beta-catenin expressionHandful of casesHeterogenous pathogenesisAbdominal distentionRectal bleedingTotal hysterectomyStromal neoplasmsOvarian massesOvarian tumorsCase reportBeta-catenin expressionSequencing analysisMuscle actinTumors
2019
Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.Peer-Reviewed Original ResearchConceptsB-cell non-Hodgkin lymphomaEBV-negative casesAggressive B-NHLPD-L1Peptide receptor radionuclide therapyAggressive B-cell lymphomasEBV-positive DLBCLEBV-positive patientsDisease-free intervalPrimary clinical outcomeYear of diagnosisEBV-positive casesReceptor radionuclide therapyExpression of SSTR2Non-Hodgkin lymphomaExpression of CD30Five yearsAvailable outcome dataB-cell lymphomaEBV negativityInitial therapyClinicopathologic characteristicsBetter prognosisCase seriesClinical outcomes